Skip to main content
Premium Trial:

Request an Annual Quote

BioMérieux Gets FDA Approval for Expanded Vitek MS Rapid Pathogen Identification

NEW YORK (GenomeWeb) – BioMérieux said today that the Vitek MS MALDI-TOF Mass Spectrometry System for rapid pathogen identification has received 510(k) clearance from the US Food and Drug Administration for the expanded identification of mycobacteria, Nocardia,and molds.

The company's database includes more than 15,000 distinct strains to provide high accuracy and enables the safe identification of the Mycobacterium tuberculosis (TB) group, the most frequent non-tuberculous mycobacteria (NTM), Nocardia, and the most medically important molds.

The company said that Vitek will offer efficient and reliable identification of these pathogens, providing clinicians with ways to manage infections such as tuberculosis, lung and bone infections, and other serious organ infections.

In order to gain FDA clearance for these new species, BioMérieux submitted information from a multi-center study consisting of 2,695 clinical isolates for 47 molds, 19 mycobacteria, and 12 Nocardia. FDA clearance of Mycobacterium species was from both solid and liquid growth media.

The competing Bruker MALDI biotyper system also received an expanded FDA approval today.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.